Samsung Bioepis Co.
Samsung Bioepis Co., Ltd.
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, Republic of Korea
Phone: +82-32-728-0114Website: https://www.samsungbioepis.com/en/index.doCareers: www.samsungbioepis.com/en/careers...
Latest news
- Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira® Biosimilar Hadlima™ (adalimumab-bwwd)
17 August 2022 - FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis
20 September 2021 - Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
18 November 2020 - Samsung Bioepis Announces One-Year Results from Phase 3 Study of SB11, a Proposed Biosimilar to Lucentis® (ranibizumab)
11 November 2020 - Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
18 May 2020 - FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
23 July 2019 - FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
27 April 2019 - FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
21 January 2019 - Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the US Food and Drug Administration
20 December 2017 - FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
24 April 2017
Drugs Associated with Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd. manufactures, markets and/or distributes more than 5 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Byooviz
Generic name: ranibizumab Drug class: anti-angiogenic ophthalmic agents |
||
|
Eticovo
Generic name: etanercept Drug class: antirheumatics, TNF alfa inhibitors |
||
|
Hadlima
Generic name: adalimumab Drug class: TNF alfa inhibitors |
||
|
Ontruzant
Generic name: trastuzumab Drug class: HER2 inhibitors |
||
|
Renflexis
Generic name: infliximab Drug class: TNF alfa inhibitors |
3 reviews | 6.7 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||